As discussed above, the genomic and immunologic features of HPV-associated HNSCC support the rationale of immunomodulatory agents, ICIs that block PD-1, PD-L1 or CTLA-4 in this population of patients. Here, PDCD1 is linked to head and neck squamous cell carcinoma.